In this study, we compared the anti-fibrotic effects of β-Pro7 Ang III to that of C21 and the currently used IPF medication, pirfenidone, in a preclinical model of BLM-induced fibrosis, the most widely used model for evaluating novel treatments for IPF [36]. This evidence concerns the gene AGT and idiopathic pulmonary fibrosis.